国际肿瘤学杂志 ›› 2016, Vol. 43 ›› Issue (3): 210-212.doi: 10.3760/cma.j.issn.1673422X.2016.03.013

• 综述 • 上一篇    下一篇

乳腺癌的辅助内分泌治疗

刘小玲,李文辉,常莉,夏耀雄   

  1. 650118 昆明医科大学第三附属医院 云南省肿瘤医院放疗科
  • 出版日期:2016-03-08 发布日期:2016-02-03
  • 通讯作者: 李文辉,Email: wenhuili64@aliyun.com E-mail:wenhuili64@aliyun.com
  • 基金资助:

    云南省卫生科技计划(2012WS0039)

Adjuvant endocrine therapy for breast cancer

Liu Xiaoling, Li Wenhui, Chang Li, Xia Yaoxiong   

  1. Department of Radiation Oncology, Yunnan Tumor Hospital, Third Affiliated Hospital of Kunming Medical University, Kunming 650118, China
  • Online:2016-03-08 Published:2016-02-03
  • Contact: Li Wenhui, Email: wenhuili64@aliyun.com E-mail:wenhuili64@aliyun.com
  • Supported by:

    Health Science and Technology Planning Project of Yunnan Province(2012WS0039)

摘要: 内分泌治疗是激素受体阳性乳腺癌患者的重要治疗手段。他莫昔芬、阿那曲唑和卵巢功能抑制剂是乳腺癌内分泌治疗中的最常用药物,针对患者疾病分期和绝经状态的不同,内分泌治疗药物的选择不同。内分泌治疗被证实有很好的疗效的同时,也被证实会产生耐药,mTOR抑制剂、CDK4/6抑制剂和纤维母细胞生长因子受体抑制剂将为内分泌治疗耐药患者带来新的希望。

关键词: 乳腺肿瘤, 雌激素类

Abstract: Endocrinotherapy is an important treatment approach for patients with hormone receptor-positive breast cancer. Tamoxifen, anastrozole and ovarian function inhibitors are the most common drugs in breast cancer endocrinotherapy. However, the choices of endocrinotherapy drugs are different on the basis of the differences in disease stages and menopausal status. Endocrinotherapy has been proved to have good effects, meanwhile, also been shown to can produce drug resistance, mTOR inhibitors, CDK4/6 inhibitors and fibroblast growth factor receptor inhibitors will bring new hope for patients with drug resistance to endocrinotherapy.

Key words: Breast neoplasms, Estrogens